Anzeige
Mehr »
Login
Samstag, 05.10.2024 Börsentäglich über 12.000 News von 690 internationalen Medien
Achtung Vervielfachung! URAN-AKTIEN starten durch …. Jetzt kaufen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
417 Leser
Artikel bewerten:
(2)

Bluebeam, Inc.: Bluebeam Revu 20: Streamline Remote Project Collaboration

Revu 20 empowers real-time collaboration across project partners worldwide, saving time and improving project quality

Pasadena, CA, Aug. 18, 2020, leading developer of solutions and services that set the standard for architecture, engineering and construction professionals worldwide, announces the newest version of Revu, their flagship project efficiency and collaboration solution. Revu 20delivers greater flexibility and control with improved user and content management capabilities and streamlines communication with new enhancements designed to increase accuracy and save time.

"When we think of 'teamwork' on a construction project, we think about removing barriers through technology while unlocking the inherent potential of a group of diverse project partners," said Bluebeam CEO Jon Elliott. "When teams have the right solutions in place to work together seamlessly across distances and time zones, all of the investments an organisation makes in training, management and process development can be realised through clear and measurable improvements in quality, accuracy and efficiency. Revu 20 delivers improved communication management capabilities and productivity improvements that are designed to maximise an organisation's investments across the board."

Revu 20 introduces new communication features that are designed to boost productivity and enable more successful project delivery, improved user and content management capabilities to provide greater flexibility and control, and enhancements to the powerful annotation tools in Revu that improve project data management when reviewing, commenting, annotating, tracking and managing project documents.

"Bluebeam has always been a company that has focused on solving problems without reinventing the way teams work in the process," said Bluebeam CPO Roger Angarita. "In fact, we focus on developing solutions that enhance the existing strength of organisations and meet them at the point where the right tools start to make all the difference. Whether that takes the form of the right features, the right collaborative tools or the right global data network. As proof to the effectiveness of our approach, Bluebeam Global Services surveyed customers at individual companies and found that 82% of Revu users reported saved time, 76% reported boosted efficiency and 88% reported improvement in work quality. These results reflect the incredible benefits of collaborative innovation and teamwork and we're proud to drive results that build a stronger business relationship among AEC companies and their customers."

Studio is a collaborative space accessed from within Revu that transforms the application into a real-time collaboration solution, allowing teams to stay connected across the globe from wherever they are - whether it's the jobsite, the trailer or - most recently - their homes. Studio Projects provide access to a single centralised location to store documents - even entire building projects - in the cloud and Revu 20 delivers improved access and control. Revu 20 also introduces an improved invitation process and administrative controls in Studio Sessions that make it easier than ever for team members and administrators worldwide to connect instantly on the same set of documents and take advantage of real-time connectivity. ?

Along with the release of Revu 20, Bluebeam also announces the launch of a Studio server in Australia today, allowing clients to host Studio Sessions and store project data within Australian borders, meeting data sovereignty requirements. Access is available immediately and is automatic for all users in the region using Revu 20 or Revu 2019. More information can be found here.

Revu 20 Standard, CAD and eXtreme editions are available now at Bluebeam.co.ukand through our worldwide reseller network.

Bluebeam, Inc.

Trusted by over 1.9 million individuals in more than 130 countries, Bluebeam's smart, intuitive annotation and collaboration solutions advance the way technical professionals work, manage and collaborate on projects digitally. Founded in Pasadena, CA, Bluebeam has grown to include additional US offices in California, Illinois, Texas and New Hampshire, as well as offices in England, Germany, Denmark, Sweden and Australia. Bluebeam is part of the Nemetschek Group. Download a 30-day trial of Bluebeam Revu on our website.

Attachment

  • Revu20Launch-IG-03 (https://ml.globenewswire.com/Resource/Download/2e6c10b1-914a-416d-a2f6-5641905cab03)
© 2020 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.